synthetic peptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-02-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
=== Human genes === Na+/K+ transporting: ATP1A1, ATP1A2, ATP1A3, ATP1A4, ATP1B1, ATP1B2, ATP1B3, ATP1B4 Ca2+ transporting: ATP2A1, ATP2A2, ATP2A3, ATP2B1, ATP2B2, ATP2B3, ATP2B4, ATP2C1, ATP2C2 H+/K+ exchanging: ATP4A H+ transporting, mitochondrial: ATP5F1A, ATP5F1B, ATP5F1C, ATP5C2, ATP5F1D, ATP5F1E, ATP5F1, ATP5MC1, ATP5MC2, ATP5MC3, ATP5PD, ATP5ME, ATP5PF, ATP5MF, ATP5MG, ATP5L2, ATP5PO, ATP5S, MT-ATP6, MT-ATP8 H+ transporting, lysosomal: ATP6AP1, ATP6AP2, ATP6V1A, ATP6V1B1, ATP6V1B2, ATP6V1C1, ATP6V1C2, ATP6V1D, ATP6V1E1, ATP6V1E2, ATP6V1F, ATP6V1G1, ATP6V1G2, ATP6V1G3, ATP6V1H, ATP6V0A1, ATP6V0A2, ATP6V0A4, ATP6V0B, ATP6V0C, ATP6V0D1, ATP6V0D2, ATP6V0E Cu2+ transporting: ATP7A, ATP7B Class I, type 8: ATP8A1, ATP8B1, ATP8B2, ATP8B3, ATP8B4 Class II, type 9: ATP9A, ATP9B Class V, type 10: ATP10A, ATP10B, ATP10D Class VI, type 11: ATP11A, ATP11B, ATP11C H+/K+ transporting, nongastric: ATP12A type 13: ATP13A1, ATP13A2, ATP13A3, ATP13A4, ATP13A5
=== Municipal politics (2025–2026) === On September 17, 2025, Findlay became the advisory board chair of the Conservative Electors Association, a newly formed municipal party in British Columbia. Her role was to help with candidate recruitment and policy development. In February 2026, Findlay was involved in a launch event for the Conservative Electors Association, where they announced the slate of candidates for the 2026 Surrey municipal election.
==== Photoreception ==== In 2015, molecular evidence was published indicating that cephalopod chromatophores are photosensitive; reverse transcription polymerase chain reactions (RT-PCR) revealed transcripts encoding rhodopsin and retinochrome within the retinas and skin of the longfin inshore squid (Doryteuthis pealeii), and the common cuttlefish (Sepia officinalis) and broadclub cuttlefish (Sepia latimanus). The authors claim this is the first evidence that cephalopod dermal tissues may possess the required combination of molecules to respond to light.
== Prognosis == IRIS has a reported mortality rate of 4.5%. Mortality rates vary and depend on the associated OI, degree of immunosuppression, geography, and access to treatment. IRIS affecting the central nervous system has generally been associated with the highest mortality rates (13-75%).
=== 2000s === Stanton was drafted by Essendon with the thirteenth overall selection in the 2003 national draft, Essendon's second pick overall in the draft. Due to many key players being injured in the 2004 pre-season, Stanton was immediately brought into the Essendon team for the round 1 match against Port Adelaide where the Bombers were comfortably defeated by 96 points. Stanton was the round nomination for the Rising Star after the round 20 win against Collingwood. Stanton started his 2005 season by changing to the number 24 jumper, previously worn by former Essendon great Joe Misiti. Stanton had a strong season, in the 19 games that he played, he averaged 18 possessions and kicked 13 goals. In just his second year of football he showed much improvement from his debut season, Stanton finished third in the 2005 Crichton Medal behind Mark Johnson and Jason Johnson with 253 votes. Stanton worked hard during the pre-season, and was able to increase his physical size. During 2006, he played a different role on the wing, opposite Scott Camporeale. During a horror season which netted only three wins and a draw for Essendon (one of which was against reigning premiers Sydney), Stanton was one of only three players in the team who played in every game that season. Stanton averaged 22 possessions and kicked 12 goals finishing fourth in the 2006 Crichton Medal with 196 votes. Stanton became a far more prominent player for the Bombers in 2007, he averaged a career-high 25 possessions in the first 10 rounds of the season.
Sources: en.wikipedia.org
However, bicalutamide does not increase sex hormone levels if combined with adequate doses of an antigonadotropin such as a GnRH modulator, estrogen, or progestogen, due to the negative feedback effects of these medications on sex-hormone production. Because bicalutamide does not lower androgen levels, it may be a particularly favorable antiandrogen for transgender women who wish to help preserve sex drive, sexual function, and/or fertility, as antiandrogens that strongly suppress levels of testosterone and its metabolites, such as CPA and GnRH modulators, can greatly disrupt these functions. Although bicalutamide has the potential to increase testosterone levels, there is no effect of this testosterone due to the blockade of the AR by bicalutamide. Neyman and colleagues in 2019 published a study on bicalutamide as a puberty blocker in adolescent transgender girls. It was employed both alone (n=17) and in combination with estrogen (n=6) at a dose of 50 mg/day in 23 transgender girls (mean age of 16 years, range 12 to 18.4 years) between 2013 and 2018. Of the girls who were treated exclusively with bicalutamide alone, 13 returned for follow-up and were analyzed. In addition to apparently showing effectiveness as an antiandrogen and puberty blocker, bicalutamide alone increased estradiol levels and promoted feminization as a secondary effect. This included breast development to Tanner stages 2 to 5 in 85% of the patients at the first follow-up visit at 6.3 months of treatment.
The chain's origin can be traced to the Dwarf Grill (now the Dwarf House), a restaurant opened by S. Truett Cathy (the chain's former chairman and CEO) in 1946 in the Atlanta suburb of Hapeville, Georgia. The original store was located near the Ford Motor Company Atlanta Assembly Plant, a source of many of the restaurant's patrons for years. It was later remodeled, reopening in 2022. In 1961, after 15 years in the fast-food business, Cathy found a pressure fryer that could cook a chicken sandwich in the same time it took to cook a hamburger. Following this discovery, he registered the name Chick-fil-A, Inc. The company's trademarked slogan, "We Didn't Invent the Chicken, Just the Chicken Sandwich," refers to their flagship menu item, the Chick-fil-A chicken sandwich. Though Chick-fil-A was the first national chain to make a fast, fried chicken sandwich its flagship item, it has been shown that Cathy's claim to have "invented the chicken sandwich" is false. From 1964 to 1967, the sandwich was licensed to over fifty eateries, including Waffle House and the concession stands of the new Houston Astrodome. The Chick-Fil-A sandwich was withdrawn from sale at other restaurants when the first dedicated location opened in 1967, in the food court of the Greenbriar Mall in Atlanta. The chain expanded in the 1970s and early 1980s by opening new locations in suburban malls' food courts. The first freestanding location was opened April 16, 1986, on North Druid Hills Road in Atlanta, Georgia, and the company began to focus more on stand-alone units rather than food courts.
=== Irish === Ancient Order of Hibernians Knights of Equity St. Patrick's Alliance of America - Founded in 1868 by members of the Friendly Sons of St. Patrick and other groups, mostly Irish Catholic. However, the Alliance's ritual emphasized freedom of religion and denounced bigotry from any source. Other elements were borrowed from the Foresters and other like groups. The Alliance's emblem was a disc showing the tree of life and the letters S. P. A. of A. The Alliance provided sick and death benefits and benefits for the loss of a wife. Membership was open to all regardless of political or religious belief as long as one was of Irish descent. There were a reported 50,000 members concentrated in "New England, Middle, Pacific Coast, and some other States". The National Secretary was based in Newark, New Jersey
== Taxonomy == This species is named in honor of Keisuke Ito, a Japanese physician and biologist. A named cultivar of this species, "Koidzumi", refers to botanist Gen'ichi Koizumi. The Japanese name of Angelica keiskei, "ashitaba" (tomorrow-leaf), stems from the above-average regenerative capabilities it exhibits after injury.
==== Alcohol metabolism ==== The best-known consequence of ALDH2 dysfunction is in relation to the consumption of ethanol. People heterozygous or homozygous for the ALDH2*2 metabolize ethanol to acetaldehyde normally but metabolize acetaldehyde poorly. As a result, they accumulate increased levels of acetaldehyde after consumption of alcoholic beverages. Effects include facial flushing (i.e. the "alcohol flush reaction"), urticaria, systemic dermatitis, and alcohol-induced respiratory reactions such as rhinitis and the exacerbation of asthma bronchoconstriction. The cited allergic reaction-like symptoms: (a) do not appear due to classical IgE or T cell-related allergen-induced reactions but rather the actions of acetaldehyde in stimulating the release of histamine, a probable mediating cause of these symptoms; (b) typically occur within 30–60 minutes of ingesting alcoholic beverages; and (c) occur in other Asian as well as non-Asian individuals that are either seriously defective in metabolizing ingested ethanol past acetaldehyde to acetic acid or, alternatively, that metabolize ethanol too rapidly for ALDH2 processing. People with a genetic ALDH2*2 deficiency have historically had a lower likelihood of developing alcoholism, both from stronger adverse effects and a possible reduction of dopamine release. However, this effect is not absolute: during the 1980s, there has been a steady increase in the number of Japanese alcoholics who carry the ALDH2*2 mutation. A strong social pressure to drink have overcome this genetic barrier to alcoholism.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.